Steven Cohen Adaptive Biotechnologies Corp Transaction History

Point72 Asset Management, L.P.

$51 Billion
Q3 2025

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 319,471 shares of ADPT stock, worth $4.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

319,471

Previous 1,373,923 76.75%

Holding current value

$4.5 Million

Previous $16 Million 70.14%

% of portfolio

0.01%

Previous 0.04%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$10.24 - $14.96 $10.8 Million - $15.8 Million	-1,054,452 Reduced 76.75%	319,471 $4.78 Million
Q2 2025 Aug 14, 2025	BUY	$6.83 - $12.16 $9.38 Million - $16.7 Million	1,373,923 New	1,373,923 $16 Million
Q4 2024 Feb 14, 2025	BUY	$4.37 - $6.78 $1.93 Million - $3 Million	441,839 Added 89.17%	937,331 $5.62 Million
Q3 2024 Nov 14, 2024	BUY	$3.37 - $5.12 $1.67 Million - $2.54 Million	495,492 New	495,492 $2.54 Million
Q1 2024 May 15, 2024	SELL	$2.88 - $4.8 $9.93 Million - $16.5 Million	-3,447,800 Reduced 92.62%	274,700 $881,000

Q4 2023 Feb 14, 2024	SELL	$3.46 - $5.33 $6.89 Million - $10.6 Million	-1,990,800 Reduced 34.85%	3,722,500 $18.2 Million
Q3 2023 Nov 14, 2023	BUY	$5.07 - $8.44 $29 Million - $48.2 Million	5,713,300 New	5,713,300 $31.1 Million
Q3 2019 Nov 15, 2019	SELL	$30.31 - $53.51 $1.52 Million - $2.68 Million	-50,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$40.3 - $48.3 $2.01 Million - $2.42 Million	50,000 New	50,000 $2.42 Million

Others Institutions Holding ADPT

# of Institutions

289

Shares Held

147M

Call Options Held

23.5K

Put Options Held

33.3K

View Full List

About Adaptive Biotechnologies Corp

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $2.01B
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

More about ADPT

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account